CPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Catalyst Pharmaceuticals Inc (CPRX) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. While the stock has positive analyst ratings and a modest price increase in the regular market, the company's recent financial performance shows declining net income, EPS, and gross margin. Additionally, no significant trading signals, news catalysts, or congress trading data support an immediate buy decision. The technical indicators suggest a neutral trend, and the options data reflects mixed sentiment. For a long-term investor, it may be better to wait for clearer growth signals or stronger catalysts before committing funds.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 66.521, and moving averages are converging, suggesting no clear trend. Key resistance is at 24.245, with support at 22.397. The stock is trading near its resistance level, which may limit immediate upside potential.
Analyst Samantha Semenkow from Citi raised the price target to $35 from $33 and maintained a Buy rating. The stock experienced a 1.89% increase in the regular market, outperforming the S&P 500.
No recent news or significant trading trends from hedge funds or insiders. Financials from Q4 2025 show declining net income (-5.79% YoY), EPS (-6.82% YoY), and gross margin (-1.84% YoY). Congress trading data is unavailable.
In Q4 2025, revenue increased by 7.61% YoY to $152.6M, but net income dropped to $52.7M (-5.79% YoY). EPS declined to $0.41 (-6.82% YoY), and gross margin fell to 76.71% (-1.84% YoY). While revenue growth is positive, declining profitability metrics are concerning.
Citi analyst Samantha Semenkow raised the price target to $35 from $33 and maintained a Buy rating. This reflects optimism about the company's future performance, but no other recent analyst updates are available.
